Holen Sie sich die Stockscreener-App
65.80
0.58%
0.38
Handel nachbörslich:
65.80
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals stock hits 52-week high at 64.89 USD By Investing.com - Investing.com Nigeria
What analysts say about Ionis Pharmaceuticals Inc ISI stockDividend Stock Watch & High Return Wealth Plans - earlytimes.in
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Applying big data sentiment scoring on Ionis Pharmaceuticals Inc.2025 Historical Comparison & Risk Controlled Stock Pick Alerts - newser.com
Should you hold or exit Ionis Pharmaceuticals Inc. nowJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock in buy zone after pullbackWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockPortfolio Gains Report & Comprehensive Market Scan Reports - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Investor Ratings Indicate Promising Upside Potential - DirectorsTalk Interviews
Published on: 2025-09-29 03:15:49 - newser.com
What drives Ionis Pharmaceuticals Inc stock priceVolume Weighted Average Price & Minimal Investment Profits - earlytimes.in
Assenagon Asset Management S.A. Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Using fundamentals and technicals on Ionis Pharmaceuticals Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
Ionis Pharmaceuticals (IONS) Is Up 5.0% After Positive Phase III Results for Alexander Disease Therapy - Yahoo Finance
IONS Upgraded by Goldman Sachs with a Significant Price Target I - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Neutral at The Goldman Sachs Group - MarketBeat
Leerink Partnrs Has Positive Outlook of IONS FY2025 Earnings - MarketBeat
Goldman Sachs Upgrades Ionis Pharmaceuticals to Neutral From Sell, Adjusts PT to $65 From $45 - MarketScreener
Ionis chalks up rare disease win with zilganersen - The Pharma Letter
Is Ionis Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Morgan Stanley Raises Ionis Pharmaceuticals (IONS) Price Target to $86 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals stock price target raised to $68 by Leerink Partners - Investing.com UK
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal - sharewise.com
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Ionis Pharmaceuticals Larger Than S&P 500 Component Align Technology - Nasdaq
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen - Biogen
A Look at Ionis Pharmaceuticals’s Valuation as Zilganersen Delivers Breakthrough Results in Alexander Disease - Sahm
Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barron's
Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News
Barclays Maintains Overweight Rating on IONS, Raises Price Targe - GuruFocus
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease - Stocktwits
Guggenheim Raises Ionis Pharmaceuticals (IONS) Price Target to $92 | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (IONS): Analyst Rating Update and Target P - GuruFocus
Guggenheim Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $83.00 at Bank of America - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Ionis Heads to FDA as Antisense Therapy Aces Pivotal Study in Rare Neurological Disease - BioSpace
IONS: HC Wainwright Reiterates Buy Rating with $95 Target | IONS Stock News - GuruFocus
Ionis reports positive results for Alexander disease drug zilganersen By Investing.com - Investing.com Nigeria
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease - BioSpace
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Sovran Advisors LLC - MarketBeat
Ionis Targets Ultra-Rare Disease Market With Zilganersen - insights.citeline.com
Ionis reports positive results for Alexander disease drug zilganersen - Investing.com India
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approval - Endpoints News
Ionis stock surges after positive results from Alexander disease drug By Investing.com - Investing.com Canada
Ionis reports promising data from study of Alexander disease therapy - Seeking Alpha
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial - Benzinga
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Ionis Pharmaceuticals (IONS) Reveals Promising Results for Zilga - GuruFocus
Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease - Nasdaq
Ionis' brain disorder drug shows promise in clinical trial - TradingView
Ionis and Sobi’s Tryngolza gains approval in EU for FCS treatment - Yahoo Finance
Wedmont Private Capital Acquires New Shares in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) - BioSpace
Will FDA Breakthrough Therapy Status for ION582 Redefine Ionis Pharmaceuticals' (IONS) Rare Disease Strategy? - Sahm
About UsGreat American Insurance GroupSpecialty Property & Casualty Insurance - FinancialContent
Stop Loss: Does Ionis Pharmaceuticals Inc stock have upside surprise potential - خودرو بانک
Levels Update: What are Ionis Pharmaceuticals Incs earnings expectationsEarnings Overview Summary & Accurate Buy Signal Alerts - خودرو بانک
2.95%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):